Amalgamated Bank has recently announced the sale of shares of Amphastar Pharmaceuticals ($NASDAQ:AMPH), Inc. through Defense World. Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing and selling generic and branded prescription drugs, active pharmaceutical ingredients, and drug delivery systems. The company has developed a wide range of generic drugs and active pharmaceutical ingredients. They specialize in developing novel formulations, manufacturing processes and drug delivery systems. The company also has a number of branded drugs in their portfolio.
It is known for its reliable quality standards and strong customer base. As Amalgamated Bank has sold shares of Amphastar Pharmaceuticals, Inc. through Defense World, investors have the opportunity to gain exposure to this growing biopharmaceutical sector. The company’s established track record of success and dedication to innovation make it an attractive choice for long-term investors.
Amphastar’s stock opened at $62.7 and managed to close at $63.1, up by 0.4% from its last closing price of $62.8. After the news of the sale broke, it witnessed a gradual increase in the share price. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Amphastar Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amphastar Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amphastar Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Amphastar Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale provides a comprehensive financial analysis of AMPHASTAR PHARMACEUTICALS. Our Risk Rating indicates that the company is a medium risk investment from both a financial and business standpoint. We have also identified two risk warnings on their balance sheet for non-financial factors. If you would like to take a more in-depth look at our analysis, we invite you to register with us. Our analysis will help you make informed decisions about investing in AMPHASTAR PHARMACEUTICALS. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Amphastar Pharmaceuticals Inc and its competitors Mallinckrodt PLC, Avadel Pharmaceuticals PLC, RPG Life Sciences Ltd is fierce. All four companies are constantly trying to one-up each other in the race to create new and innovative drugs. This competition is good for the consumer, as it drives down prices and forces the companies to be constantly innovating.
Avadel Pharmaceuticals PLC is a pharmaceutical company with a market capitalization of 356.22 million as of 2022. The company’s return on equity is -255.63%. Avadel Pharmaceuticals PLC is engaged in the development, manufacture, and commercialization of pharmaceutical products. The company’s products include drugs for the treatment of sleep disorders, urinary incontinence, and attention deficit hyperactivity disorder.
– Avadel Pharmaceuticals PLC ($BSE:532983)
Life sciences is the study of living organisms, including plants, animals, and human beings. The company’s market cap is 14.42B as of 2022, a Return on Equity of 19.69%. The company focuses on the research and development of new drugs and therapies to treat diseases.
Amphastar Pharmaceuticals, Inc. is a growing biopharmaceutical company that develops, manufactures, and markets generic and branded injectable and inhalation products. Analysts suggest that the company has an attractive pipeline of innovative products and possess a strong financial position with significant cash reserves. Furthermore, it is expected that Amphastar’s presence in the generic injectable and inhalation markets will continue to expand in the future.
Additionally, the company has established strategic collaborations with leading healthcare companies that are expected to drive new opportunities in the near future. All in all, Amphastar Pharmaceuticals, Inc. seems to be an attractive long-term investment for investors with an appetite for risk.